Hostname: page-component-89b8bd64d-n8gtw Total loading time: 0 Render date: 2026-05-13T17:18:26.203Z Has data issue: false hasContentIssue false
  • English
  • Français

An Irish case of pulmonary emboli secondary to clozapine therapy

Published online by Cambridge University Press:  13 June 2014

Conor O'Luanaigh  and
Paul Scully
Conor O'Luanaigh
Affiliation:
St Patrick's Hospital, James's Street, Dublin 8
Paul Scully
Affiliation:
Jonathan Swift Clinic, St James's Hospital, James's Street, Dublin 8
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: Clozapine is the prototype atypical antipsychotic used for treatment-resistant schizophrenia, but its use has been limited by the well-established association with agranulocytosis. An increased risk of other serious adverse events such as myocarditis and thromboembolism has also been suggested to be associated with clozapine therapy.

Aims: We describe an Irish case of multiple pulmonary emboli detected by CT pulmonary angiogram thought to be secondary to clozapine therapy.

Conclusion: Although clozapine is a very efficacious antipsychotic its many side-effects limit its use. Pulmonary embolism must be remembered as a potential rare side-effect in clozapine therapy. Underlying mechanisms are still unclear although several have been proposed.

Information

Type
Case report
Information
Irish Journal of Psychological Medicine , Volume 23 , Issue 1 , March 2006 , pp. 36 - 37
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Kane, J, Honifeld, G, Singer, Jet al.Clozapine for the treatment resistant schizophrenic. Archives of General Psychiatry 1988; 45: 789–796CrossRefGoogle ScholarPubMed
2.Ungvari, G. Neuroleptic related sudden death (proven or a mere hypothesis?). Pharmacopsychiatry 1980; 13: 29–33CrossRefGoogle ScholarPubMed
3.Hafner, H, Brehm, I. Thromboembolic complications in neuroleptic treatment. Compr Psychiatry 1965; 6: 25–34CrossRefGoogle Scholar
4.Thomassen, R, Vandenbroucke, JP, Rosendaal, FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001; 179: 63–66CrossRefGoogle ScholarPubMed
5.Lacika, S, Cooper, JP. Pulmonary embolus possibly associated with clozapine treatment. Can J Psychiatry 1999; 44: 396–397Google ScholarPubMed
6.Hagg, S, Spigset, O, Soderstrom, TG. Association of venous thromboembolism and clozapine. Lancet 2000; 335: 1155–1156.CrossRefGoogle Scholar
7.Walker, AM, Lanza, LL, Arellano, F, Rothman, KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671–677CrossRefGoogle ScholarPubMed
8.Davis, S, Kern, HB, Asokan, R. Antiphospholipid antibodies associated with clozapine treatment. Am J Hematology 1994; 46: 166–167CrossRefGoogle ScholarPubMed
9.Canoso, RT, de Oliveira, RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematology 1988; 27: 272–275CrossRefGoogle ScholarPubMed
10.Boullin, DJ, Woods, HF, Grimes, RPJ, Grahame-Smith, DG, Wiles, Det al.Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacology 1975; 2: 29–35CrossRefGoogle ScholarPubMed
11.Orr, MW, Boullin, DJ. The relationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine. Br J Clin Pharmacology 1976; 3: 925–928CrossRefGoogle Scholar
12.Love, RCNovel versus conventional antipsychotic drugs. Pharmacotherapy 1996; 16:6S–10SCrossRefGoogle ScholarPubMed